Study explores intratumoral microbiota as a novel frontier in cancer research

Researchers review the role of intratumoral microbiota in cancer development, suggesting its potential in predicting and treating various cancers.

New diagnostic guidelines aim to distinguish common memory disorder from Alzheimer’s

LATE-NC diagnostic criteria improve differentiation from Alzheimer’s, addressing challenges in memory-loss syndromes and guiding therapeutic interventions.

January 28, 2025

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 – Biotech Investments

Issuer: Mainz BioMed N.V. / Key word(s): Study results/Conference 03.06.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz

June 4, 2024

FDA approves Amicus’ Pombiliti + Opfolda combo therapy for Pompe disease

The FDA on Thursday approved Amicus Therapeutics’ combo therapy for a rare inherited lysosomal disorder called Pompe disease following several regulatory delays. The drugs are

September 29, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.